For women with breast hypertrophy, the burden of neurological symptoms may extend far beyond musculoskeletal discomfort — and the clinical picture emerging from structured data challenges how headache medicine and insurance criteria approach this condition. Understanding which specific pain phenotypes are disproportionately prevalent in macromastia could reshape referral pathways and treatment decisions for a population often underserved by neurology.
This retrospective cross-sectional analysis, published in Headache, examined women diagnosed with macromastia (ICD-10 code N62) treated at an academic neurology practice between 2017 and 2024, matched by age, race-ethnicity, and BMI to control patients without macromastia using propensity scoring. The study evaluated the prevalence of chronic migraine, neck pain, cervical radiculopathy, occipital neuralgia, and obstructive sleep apnea (OSA) across both groups, while also analyzing factors associated with receipt of reduction mammoplasty. The dual focus on craniocervical pain phenotypes and sleep-disordered breathing is notably broader than prior work, which has largely treated headache as a monolithic complaint rather than a heterogeneous cluster of diagnosable conditions.
The association between macromastia and specific headache disorders like chronic migraine and occipital neuralgia is mechanistically plausible: increased anterior chest wall mass alters cervical posture, potentially compressing occipital nerve roots and creating chronic myofascial tension that sensitizes trigeminal pathways. The OSA connection is less intuitive but may relate to increased parapharyngeal soft tissue burden and altered sleep posture. Several important limitations temper interpretation: the retrospective design captures coded diagnoses rather than clinician-adjudicated phenotypes, the academic neurology setting introduces significant referral bias, and cross-sectional data cannot establish causality. Whether breast reduction surgery meaningfully reduces headache frequency — a claim insurers implicitly accept — remains inadequately supported by prospective controlled evidence. This study is best characterized as hypothesis-generating, providing a foundation for the longitudinal trials this clinical question urgently requires.